For the quarter ended September 2026, Alnylam Pharmaceuticals (ALNY Quick QuoteALNY - Free Report) reported revenue of $1.46 billion, up 16.7% over the same period last year. EPS came in at $16.26, compared to $2.90 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $1.45 billion, representing a surprise of +0.63%. The company delivered an EPS surprise of +642.47%, with the consensus EPS estimate being $2.19.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Alnylam performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Product revenues, net: $1.29 billion versus $1.3 billion estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +51.8% change.
• Revenues- Net revenues from collaborations: $71.48 million compared to the $65.92 million average estimate based on five analysts.
• Revenues- Royalty revenue: $94.66 million compared to the $82.08 million average estimate based on five analysts. The reported number represents a change of +104.9% year over year.
• Net Product Revenue - Total TTR: $1.15 billion versus the four-analyst average estimate of $1.17 billion.
• Net Product Revenue- Oxlumo: $52.5 million versus the four-analyst average estimate of $55.69 million. The reported number represents a year-over-year change of -0.6%.
• Net Product Revenue- Givlaari: $89.49 million compared to the $87.1 million average estimate based on four analysts. The reported number represents a change of +21.1% year over year.
• Net Product Revenue - Total Rare: $141.99 million versus $144.71 million estimated by four analysts on average.
• Net Product Revenue- Onpattro: $19.6 million versus the three-analyst average estimate of $22.27 million. The reported number represents a year-over-year change of -49.9%.
• Net Product Revenue- Amvuttra: $1.13 billion versus $1.15 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +64.9% change.

View all Key Company Metrics for Alnylam here>>>

Shares of Alnylam have returned -5.8% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.